Vela Technologies #VELA – Quarterly Investment Update August 30, 2024 – Posted in: Uncategorized, Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 30 June 2024. Key numbers as at 30 June 2024* · The value of Vela’s total assets (including cash) decreased during the quarter by £2,737,000 to £2,804,000 (quarter to 31 March 2024 – a decrease of £640,000 to £5,541,000). · This decrease is entirely attributable to the collapse…

Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released by Conduit Pharmaceuticals Inc. (“Conduit”) on 8 August 2024 regarding Conduit entering into an exclusive licence agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments. Vela holds 1,005,760 common shares in Conduit representing 0.46% of Conduit’s issued share capital. At the closing mid-market price of $0.17 on 8 August 2024,…

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee company Conduit Pharmaceuticals has entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders. Under the terms of the License Agreement,…

Vela Technologies #VELA – Investee co Conduit Pharmaceuticals secures $2.65 million funding – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee pharmaceutical co Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has entered into a financing agreement securing $2.65 million through a Senior Secured Promissory Note with Nirland Limited. The agreement, effective Monday, includes an issuance of 12.5 million shares of common stock to the purchaser. The promissory note carries an annual interest rate of 12%, accruing daily, with the option for the purchaser to receive interest payments in cash or…

Vela Technologies #VELA – Total Voting Rights July 31, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, announces that the Company’s issued share capital as at the date of this announcement comprises 18,970,695,255 ordinary shares of 0.01 pence each (“Ordinary Shares”) with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 18,970,695,255. The above…

Vela Technologies #VELA – Chairman Spends £25,500 and buys 30m shares – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, was informed that, on 30 July 2024, Nigel Brent Fitzpatrick, Non-Executive Chairman, bought 30,000,000 ordinary shares of 0.01 pence each in the Company (“Ordinary Shares”) at 0.0085p per Ordinary Share. Following the above purchase Mr Fitzpatrick now has a total beneficial interest in 31,500,000 Ordinary Shares, equivalent to approximately 0.17 per cent. of the Company’s issued…

Vela Technologies #VELA – Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases July 17, 2024 – Posted in: Vela Technologies Plc (VELA)

Read here Conduit Pharmaceuticals Inc. (Nasdaq: CDT) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed…

Vela Technologies #VELA – Investment in Hamak Gold Limited – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, announces that it has entered into an unsecured convertible loan note instrument (“the Agreement”) with Hamak Gold Limited (“Hamak”), the Liberia-based gold exploration and development company (LSE:HAMA). As part of the Agreement, Vela has agreed to issue 2,424,242,424 new ordinary shares of 0.01 pence each (“the Consideration Shares”) to Hamak at a deemed issue price of 0.012375 pence…

Vela Technologies #VELA – Investee Co EnSilica #ENSI EnSilica wins new supply order for Edge AI Chip July 15, 2024 – Posted in: Vela Technologies Plc (VELA)

EnSilica, a leading chip maker of mixed signal ASICs (Application Specific Integrated Circuits), is pleased to announce a US$7 million order from a new customer (the “Order”). The Order is for the masking – being the non-recurring engineering (“NRE”) component – and initial wafer supply for an edge artificial intelligence (“AI”)* processing chip. Based on the customer forecasts, approximately US$5 million of revenue is expected to fall into the Company’s current financial year. There is a further…

Vela Technologies #VELA – Major shareholding in investee co Northcoders #CODE June 11, 2024 – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA – TR1: Notes that Dowgate Group Limited has acquired 420,000 shares in investee co Northcoders #CODE, and now owns 5.24% of the company. Full TR1 here: https://www.londonstockexchange.com/news-article/CODE/notification-of-major-holdings/16513877

« First
1
2
3
4
5
...
9
Next
Last »